Gliomatosis cerebri: Clinical, neurochemical and neuroradiological response to temozolomide administration

R. Lodi, E. Setola, C. Tonon, P. Ambrosetto, E. Franceschi, L. Crinò, B. Barbiroli, P. Cortelli

Research output: Contribution to journalArticlepeer-review


Gliomatosis cerebri is a rare form of diffusely infiltrating glioma that is typically resistant to conventional chemotherapy and radiation therapy and carries a poor prognosis. Temozolomide has shown antineoplastic activity against malignant gliomas and more recently was beneficial in one patient with gliomatosis cerebri. To make an objective assessment of the effect of long-term temozolomide administration in a patient with gliomatosis cerebri we used brain proton magnetic resonance spectroscopy and structural MRI. A 46-year-old man with gliomatosis cerebri was treated with temozolomide (200 mg/m2 per day for 5 days every 28 days). Twenty cycles of temozolomide resulted in a marked reduction in choline and scyllo-inositol content, as detected using brain proton MR spectroscopy, indicating reduced tumor cellularity and/or growth rate. Neurochemical improvements were associated with normalization of the signal intensity in most of the previously affected cerebral regions and regression of mass effect on MRI. A left pyramidal syndrome, present at the start of the treatment, disappeared. Our observation lends support to larger clinical trials evaluating the use of temozolomide to treat this brain tumor.

Original languageEnglish
Pages (from-to)1003-1007
Number of pages5
JournalMagnetic Resonance Imaging
Issue number9
Publication statusPublished - Nov 2003


  • Gliomatosis cerebri
  • Proton MR spectroscopy
  • Temozolomide

ASJC Scopus subject areas

  • Biophysics
  • Clinical Biochemistry
  • Structural Biology
  • Radiology Nuclear Medicine and imaging
  • Condensed Matter Physics


Dive into the research topics of 'Gliomatosis cerebri: Clinical, neurochemical and neuroradiological response to temozolomide administration'. Together they form a unique fingerprint.

Cite this